Análisis de la eficacia de las nuevas terapias en el tratamiento de la esclerosis lateral amiotrófica
Analysis of the efficacy of new therapies in the treatment of amyotrophic lateral sclerosis
Resumen
RESUMEN
La esclerosis lateral amiotrófica (ELA) es una enfermedad neurodegenerativa que compromete a las motoneuronas superiores e inferiores, caracterizándose por la pérdida progresiva de sus funciones lo que conlleva debilidad muscular, parálisis, y, finalmente, insuficiencia respiratoria que lleva a la muerte del paciente. Es considerada una enfermedad catastrófica y aún no se ha encontrado una cura, por ello, esta investigación tiene como objetivo proporcionar los avances en tratamientos para ELA, identificando nuevos fármacos y evaluando su eficacia en comparación con las terapias convencionales. Se realizó una revisión de artículos científicos publicados entre 2019 y 2024, obtenidos mediante fórmulas en bases de datos: PubMed, Web of Sciencie, Scopus y Biblioteca Virtual de Salud. Se obtuvieron 43 publicaciones de las cuales 29 fueron ensayos clínicos y 14 revisiones de la literatura. Los principales hallazgos fueron fármacos en distintas dianas terapéuticas y terapias con células madre. Se concluyen que los nuevos tratamientos para ELA se agrupan en fármacos para disminuir el daño neuronal a través de distintos mecanismos y terapias en base de células madre, las terapias inmunológicas no fueron concluyentes en esta revisión.
ABSTRACT
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that involves the upper and lower motor neurons, characterized by progressive loss of function leading to muscle weakness, paralysis, and, finally, respiratory failure leading to death of the patient. It is considered a catastrophic disease and a cure has not yet been found, therefore, this research aims to provide advances in treatments for ALS, identifying new drugs and evaluating their efficacy compared to conventional therapies. A review of scientific articles published between 2019 and 2024 was performed, the articles were obtained using formulas in databases: PubMed, Web of Sciencie, Scopus and Virtual Health Library. Forty-three publications were obtained of which 29 were clinical trials and 14 literature reviews. The main findings were drugs in different therapeutic targets and stem cell therapies. It is concluded that new treatments for ALS are grouped into drugs to reduce neuronal damage through different mechanisms and stem cell-based therapies; immunological therapies were not conclusive in this review.
Recibido: 08-01-2025
Aceptado: 13-02-2025
Publicado: 28-02-2025
Palabras clave
Texto completo:
PDFReferencias
Aizawa, H., Kato, H., Oba, K., Kawahara, T., Okubo, Y., Saito, T., Naito, M., Urushitani, M., Tamaoka, A., Nakamagoe, K., Ishii, K., Kanda, T., Katsuno, M., Atsuta, N., Maeda, Y., Nagai, M., Nishiyama, K., Ishiura, H., Toda, T., … Kwak, S. (2022). Randomized phase 2 study of perampanel for sporadic amyotrophic lateral sclerosis. Journal of Neurology, 269(2), 885–896. https://doi.org/10.1007/s00415-021-10670-y
Aktekin, M., y Uysal, H. (2020). Epidemiology of amyotrophic lateral sclerosis. Turkish Journal Of Neurology, 26(3). https://jag.journalagent.com/tjn/pdfs/TJN_26_3_187_196%5BA%5D.pdf
Al-Chalabi, A., Shaw, P., Leigh, P. N., van den Berg, L., Hardiman, O., Ludolph, A., Aho, V. V, Sarapohja, T., y Kuoppamäki, M. (2019). Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial. Journal of Neurology, Neurosurgery & Amp; Psychiatry, 90(10), 1165. https://doi.org/10.1136/jnnp-2018-320288
Andrew, A. S., Bradley, W. G., Peipert, D., Butt, T., Amoako, K., Pioro, E. P., Tandan, R., Novak, J., Quick, A., & Pugar, K. D. (2021). Risk factors for amyotrophic lateral sclerosis: a regional United States case‐control study. Muscle & Nerve, 63(1), 52–59. https://onlinelibrary.wiley.com/doi/full/10.1002/mus.27085
Barczewska, M., Maksymowicz, S., Zdolińska-Malinowska, I., Siwek, T., y Grudniak, M. (2020). Umbilical Cord Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis: an Original Study. Stem Cell Reviews and Reports, 16(5), 922–932. https://doi.org/10.1007/s12015-020-10016-7
Bassani, D., Pavan, M., Federico, S., Spalluto, G., Sturlese, M., y Moro, S. (2022). The Multifaceted Role of GPCRs in Amyotrophic Lateral Sclerosis: A New Therapeutic Perspective? International Journal of Molecular Sciences, 23(9). https://doi.org/10.3390/ijms23094504
Benatar, M., Hansen, T., Rom, D., Geist, M. A., Blaettler, T., Camu, W., Kuzma-Kozakiewicz, M., van den Berg, L. H., Morales, R. J., Chio, A., Andersen, P. M., Pradat, P.-F., Lange, D., Van Damme, P., Mora, G., Grudniak, M., Elliott, M., Petri, S., Olney, N., … Levine, T. (2024). Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. The Lancet Neurology, 23(7), 687–699. https://doi.org/10.1016/S1474-4422(24)00134-0
Benussi, A., Cantoni, V., Grassi, M., Libri, I., Cotelli, M. S., Tarantino, B., Datta, A., Thomas, C., Huber, N., Kärkkäinen, S., Herukka, S.-K., Haapasalo, A., Filosto, M., Padovani, A., & Borroni, B. (2023). Cortico-spinal tDCS in amyotrophic lateral sclerosis: A randomized, double-blind, sham-controlled trial followed by an open-label phase. Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation, 16(6), 1666–1676. https://doi.org/10.1016/j.brs.2023.11.008
Berry, J. D., Cudkowicz, M. E., Windebank, A. J., Staff, N. P., Owegi, M., Nicholson, K., McKenna-Yasek, D., Levy, Y. S., Abramov, N., & Kaspi, H. (2019). NurOwn, phase 2, randomized, clinical trial in patients with ALS: safety, clinical, and biomarker results. Neurology, 93(24), e2294–e2305. https://doi.org/10.1212/WNL.0000000000008620
Boros, B. D., Schoch, K. M., Kreple, C. J., & Miller, T. M. (2022). Antisense Oligonucleotides for the Study and Treatment of ALS. Neurotherapeutics, 19(4), 1145–1158. 10.1007/s13311-022-01247-2
Camu, W., Mickunas, M., Veyrune, J.-L., Payan, C., Garlanda, C., Locati, M., Juntas-Morales, R., Pageot, N., Malaspina, A., Andreasson, U., Kirby, J., Suehs, C., Saker, S., Masseguin, C., De Vos, J., Zetterberg, H., Shaw, P. J., Al-Chalabi, A., Leigh, P. N., … Bensimon, G. (2020). Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial. EBioMedicine, 59. https://doi.org/10.1016/j.ebiom.2020.102844
Chen, P.-C., Hsieh, Y.-C., Huang, C.-C., & Hu, C.-J. (2020). Tamoxifen for amyotrophic lateral sclerosis: A randomized double-blind clinical trial. Medicine, 99(22). https://journals.lww.com/md-journal/fulltext/2020/05290/tamoxifen_for_amyotrophic_lateral_sclerosis__a.85.aspx
Corcia, P., Beltran, S., Bakkouche, S. E., & Couratier, P. (2021). Therapeutic news in ALS. Revue Neurologique, 177(5), 544–549. https://doi.org/https://doi.org/10.1016/j.neurol.2020.12.003
Corey, D. (2020, November 17). BrainStorm Announces Topline Results from NurOwn® Phase 3 ALS Study. BrainStorm Cell Therapeutics. https://ir.brainstorm-cell.com/2020-11-17-BrainStorm-Announces-Topline-Results-from-NurOwn-R-Phase-3-ALS-Study
DailyMed. (2023, April 3). RELYVRIO- sodium phenylbutyrate/taurursodiol powder, for suspension. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=126747c4-39f3-4e20-8f3c-7b8596d8ba7d
Dalla Bella, E., Bersano, E., Antonini, G., Borghero, G., Capasso, M., Caponnetto, C., Chiò, A., Corbo, M., Filosto, M., Giannini, F., Spataro, R., Lunetta, C., Mandrioli, J., Messina, S., Monsurrò, M. R., Mora, G., Riva, N., Rizzi, R., Siciliano, G., … Lauria, G. (2021). The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trial. Brain, 144(9), 2635–2647. https://doi.org/10.1093/brain/awab167
D’Antona, S., Caramenti, M., Porro, D., Castiglioni, I., & Cava, C. (2021). Amyotrophic Lateral Sclerosis: A Diet Review. Foods, 10(12). https://doi.org/10.3390/foods10123128
Feldman, E. L., Goutman, S. A., Petri, S., Mazzini, L., Savelieff, M. G., Shaw, P. J., & Sobue, G. (2022). Amyotrophic lateral sclerosis. The Lancet, 400(10360), 1363–1380. https://doi.org/10.1016/S0140-6736(22)01272-7
Ferraiuolo, L., & Maragakis, N. J. (2021). Mini-Review: Induced pluripotent stem cells and the search for new cell-specific ALS therapeutic targets. Neuroscience Letters, 755, 135911. https://doi.org/https://doi.org/10.1016/j.neulet.2021.135911
Gebrehiwet, P., Meng, L., Rudnicki, S. A., Sarocco, P., Wei, J., Wolff, A. A., Butzner, M., Chiò, A., Andrews, J. A., Genge, A., Hughes, D. A., Jackson, C. E., Lechtzin, N., Miller, T. M., & Shefner, J. M. (2023). Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS. Journal of Medical Economics, 26(1), 488–493. https://doi.org/10.1080/13696998.2023.2192588
Genge, A., van den Berg, L. H., Frick, G., Han, S., Abikoff, C., Simmons, A., Lin, Q., Patra, K., Kupperman, E., & Berry, J. D. (2023). Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Neurology, 80(10), 1089–1097. https://doi.org/10.1001/jamaneurol.2023.2851
Gotkine, M., Caraco, Y., Lerner, Y., Blotnick, S., Wanounou, M., Slutsky, S. G., Chebath, J., Kuperstein, G., Estrin, E., Ben-Hur, T., Hasson, A., Molakandov, K., Sonnenfeld, T., Stark, Y., Revel, A., Revel, M., & Izrael, M. (2023). Safety and efficacy of first-in-man intrathecal injection of human astrocytes (AstroRx®) in ALS patients: phase I/IIa clinical trial results. Journal of Translational Medicine, 21(1), 122. https://doi.org/10.1186/s12967-023-03903-3
Henderson, R. D., Agosti, J. M., McCombe, P. A., Thorpe, K., Heggie, S., Heshmat, S., Appleby, M. W., Ziegelaar, B. W., Crowe, D. T., y Redlich, G. L. (2021). Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis. Medicine, 100(42). https://journals.lww.com/md-journal/fulltext/2021/10220/phase_1b_dose_escalation,_safety,_and.12.aspx
Hoxhaj, P., Hastings, N., Kachhadia, M. P., Gupta, R., Sindhu, U., Durve, S. A., Azam, A., Auz Vinueza, M. J., B., Win, S. H., Rathod, D. C., & Afsar, A. P. (2023). Exploring Advancements in the Treatment of Amyotrophic Lateral Sclerosis: A Comprehensive Review of Current Modalities and Future Prospects. Cureus, 15(9), e45489. https://doi.org/10.7759/cureus.45489
Iannitti, T., y Palmieri, B. (2011). Clinical and Experimental Applications of Sodium Phenylbutyrate. Drugs in R & D, 11(3), 227–249. https://doi.org/10.2165/11591280-000000000-00000
Jiang, J., Wang, Y., & Deng, M. (2022). New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022. Frontiers in Pharmacology, 13, 1054006. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.1054006/full
Ketabforoush, A., Faghihi, F., Azedi, F., Ariaei, A., Habibi, M. A., Khalili, M., Ashtiani, B. H., Joghataei, M. T., & Arnold, W. D. (2024). Sodium Phenylbutyrate and Tauroursodeoxycholic Acid: A Story of Hope Turned to Disappointment in Amyotrophic Lateral Sclerosis Treatment. Clinical Drug Investigation, 44(7), 495–512. https://doi.org/10.1007/s40261-024-01371-1
Ketabforoush, A. H. M. E., Chegini, R., Barati, S., Tahmasebi, F., Moghisseh, B., Joghataei, M. T., Faghihi, F., & Azedi, F. (2023). Masitinib: The promising actor in the next season of the Amyotrophic Lateral Sclerosis treatment series. Biomedicine y Pharmacotherapy, 160, 114378. https://doi.org/https://doi.org/10.1016/j.biopha.2023.114378
Kiernan, M. C., Vucic, S., Talbot, K., McDermott, C. J., Hardiman, O., Shefner, J. M., Al-Chalabi, A., Huynh, W., Cudkowicz, M., Talman, P., Van den Berg, L. H., Dharmadasa, T., Wicks, P., Reilly, C., & Turner, M. R. (2021). Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nature Reviews Neurology, 17(2), 104–118. https://doi.org/10.1038/s41582-020-00434-z
Kwon, H. S., & Koh, S.-H. (2020). Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Translational Neurodegeneration, 9(1), 42. https://doi.org/10.1186/s40035-020-00221-2
Legare, C. A., Raup-Konsavage, W. M., & Vrana, K. E. (2022). Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals. Pharmacology, 107(3–4), 131–149. https://doi.org/10.1159/000521683
Li, X., & Bedlack, R. (2024). Evaluating emerging drugs in phase II y III for the treatment of amyotrophic lateral sclerosis. Expert Opinion on Emerging Drugs, 29(2), 93–102. https://doi.org/10.1080/14728214.2024.2333420
Mandrioli, J., D’Amico, R., Zucchi, E., De Biasi, S., Banchelli, F., Martinelli, I., Simonini, C., Lo Tartaro, D., Vicini, R., Fini, N., Gianferrari, G., Pinti, M., Lunetta, C., Gerardi, F., Tarlarini, C., Mazzini, L., De Marchi, F., Scognamiglio, A., Sorarù, G., … Cossarizza, A. (2023). Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis. Nature Communications, 14(1), 4970. https://doi.org/10.1038/s41467-023-40734-8
Marvulli, R., Megna, M., Citraro, A., Vacca, E., Napolitano, M., Gallo, G., Fiore, P., & Ianieri, G. (2019). Botulinum Toxin Type A and Physiotherapy in Spasticity of the Lower Limbs Due to Amyotrophic Lateral Sclerosis. Toxins, 11(7). https://doi.org/10.3390/toxins11070381
Masrori, P., & Van Damme, P. (2020). Amyotrophic lateral sclerosis: a clinical review. European Journal of Neurology, 27(10), 1918–1929. https://doi.org/10.1111/ene.14393
Mazzini, L., Gelati, M., Profico, D. C., Sorarù, G., Ferrari, D., Copetti, M., Muzi, G., Ricciolini, C., Carletti, S., Giorgi, C., Spera, C., Frondizi, D., Masiero, S., Stecco, A., Cisari, C., Bersano, E., De Marchi, F., Sarnelli, M. F., Querin, G., … Group, on behalf of the A.-Nsc. T. S. (2019). Results from Phase I Clinical Trial with Intraspinal Injection of Neural Stem Cells in Amyotrophic Lateral Sclerosis: A Long-Term Outcome. Stem Cells Translational Medicine, 8(9), 887–897. https://doi.org/10.1002/sctm.18-0154
Mead, R. J., Shan, N., Reiser, H. J., Marshall, F., & Shaw, P. J. (2023). Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. Nature Reviews Drug Discovery, 22(3), 185–212. https://doi.org/10.1038/s41573-022-00612-2
Milligan, C., Atassi, N., Babu, S., Barohn, R. J., Caress, J. B., Cudkowicz, M. E., Evora, A., Hawkins, G. A., Wosiski-Kuhn, M., Macklin, E. A., Shefner, J. M., Simmons, Z., Bowser, R. P., & Ladha, S. S. (2021). Tocilizumab is safe and tolerable and reduces C-reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients. Muscle & Nerve, 64(3), 309–320. https://doi.org/https://doi.org/10.1002/mus.27339
Morimoto, S., Takahashi, S., Ito, D., Daté, Y., Okada, K., Kato, C., Nakamura, S., Ozawa, F., Chyi, C. M., Nishiyama, A., Suzuki, N., Fujimori, K., Kondo, T., Takao, M., Hirai, M., Kabe, Y., Suematsu, M., Jinzaki, M., Aoki, M., … Okano, H. (2023). Phase 1/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery. Cell Stem Cell, 30(6), 766-780.e9. https://doi.org/10.1016/j.stem.2023.04.017
Noor Eddin, A., Alfuwais, M., Noor Eddin, R., Alkattan, K., & Yaqinuddin, A. (2024). Gut-Modulating Agents and Amyotrophic Lateral Sclerosis: Current Evidence and Future Perspectives. Nutrients, 16(5). https://doi.org/10.3390/nu16050590
Obrador, E., Salvador, R., López-Blanch, R., Jihad-Jebbar, A., Vallés, S. L., & Estrela, J. M. (2020). Oxidative stress, neuroinflammation and mitochondria in the pathophysiology of amyotrophic lateral sclerosis. Antioxidants, 9(9), 901. https://www.mdpi.com/2076-3921/9/9/901
Oki, R., Izumi, Y., Fujita, K., Miyamoto, R., Nodera, H., Sato, Y., Sakaguchi, S., Nokihara, H., Kanai, K., Tsunemi, T., Hattori, N., Hatanaka, Y., Sonoo, M., Atsuta, N., Sobue, G., Shimizu, T., Shibuya, K., Ikeda, K., Kano, O., … Collaborators, J. E.-S. T. of U.-D. M. for A. L. S. (JETALS). (2022). Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Neurology, 79(6), 575–583. https://doi.org/10.1001/jamaneurol.2022.0901
Ortega-Hombrados, L., Molina-Torres, G., Galán-Mercant, A., Sánchez-Guerrero, E., González-Sánchez, M., & Ruiz-Muñoz, M. (2021). Systematic Review of Therapeutic Physical Exercise in Patients with Amyotrophic Lateral Sclerosis over Time. International Journal of Environmental Research and Public Health, 18(3). https://doi.org/10.3390/ijerph18031074
Paganoni, S., Hendrix, S., Dickson, S. P., Knowlton, N., Macklin, E. A., Berry, J. D., Elliott, M. A., Maiser, S., Karam, C., Caress, J. B., Owegi, M. A., Quick, A., Wymer, J., Goutman, S. A., Heitzman, D., Heiman-Patterson, T. D., Jackson, C. E., Quinn, C., Rothstein, J. D., … Cudkowicz, M. E. (2021). Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle y Nerve, 63(1), 31–39. https://doi.org/https://doi.org/10.1002/mus.27091
Paganoni, S., Macklin, E. A., Hendrix, S., Berry, J. D., Elliott, M. A., Maiser, S., Karam, C., Caress, J. B., Owegi, M. A., Quick, A., Wymer, J., Goutman, S. A., Heitzman, D., Heiman-Patterson, T., Jackson, C. E., Quinn, C., Rothstein, J. D., Kasarskis, E. J., Katz, J., … Cudkowicz, M. E. (2020). Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis. New England Journal of Medicine, 383(10), 919–930. https://doi.org/10.1056/NEJMoa1916945
Paganoni, S., Quintana, M., Sherman, A. V, Vestrucci, M., Wu, Y., Timmons, J., Cudkowicz, M., & Consortium, the P. R. O.-A. A. L. S. C. T. (2023). Analysis of sodium phenylbutyrate and taurursodiol survival effect in ALS using external controls. Annals of Clinical and Translational Neurology, 10(12), 2297–2304. https://doi.org/https://doi.org/10.1002/acn3.51915
Palomo, V., Nozal, V., Rojas-Prats, E., Gil, C., & Martinez, A. (2021). Protein kinase inhibitors for amyotrophic lateral sclerosis therapy. British Journal of Pharmacology, 178(6), 1316–1335. https://doi.org/https://doi.org/10.1111/bph.15221
Petrou, P., Kassis, I., Yaghmour, N. E., Ginzberg, A., & Karussis, D. (2021). A phase II clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis. FBL, 26(10), 693–706.
Potenza, R. L., Armida, M., & Popoli, P. (2024). Can Some Anticancer Drugs Be Repurposed to Treat Amyotrophic Lateral Sclerosis? A Brief Narrative Review. International Journal of Molecular Sciences, 25(3). https://doi.org/10.3390/ijms25031751
Povedano, M., Paipa, A., Barceló, M., Woodward, M. K., Ortega, S., Domínguez, R., Aragonés, M. E., Horrillo, R., Costa, M., & Páez, A. (2022). Plasma exchange with albumin replacement and disease progression in amyotrophic lateral sclerosis: a pilot study. Neurological Sciences, 43(5), 3211–3221. https://doi.org/10.1007/s10072-021-05723-z
Rare Daily Staff. (2024, March 27). TUDCA-ALS Late-Stage Trial in ALS Patients Fails. Global Genes. https://globalgenes.org/raredaily/tudca-als-late-stage-trial-in-als-patients-fails/
Riva, N., Mora, G., Sorarù, G., Lunetta, C., Ferraro, O. E., Falzone, Y., Leocani, L., Fazio, R., Comola, M., Comi, G., Formaglio, F., Rossi, P., Clerici, M., Falzone, Y. M., Pozzi, L., Martinelli, D., Cerri, F., Lopez, I. D., Martinelli-Boneschi, F., … Chio, A. (2019). Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet Neurology, 18(2), 155–164. https://doi.org/10.1016/S1474-4422(18)30406-X
Rokade, A. V, Yelne, P., & Giri, A. (2022). Riluzole and edavarone: The hope against amyotrophic lateral sclerosis. Cureus, 14(10). 10.7759/cureus.30035
Salomon-Zimri, S., Pushett, A., Russek-Blum, N., Van Eijk, R. P. A., Birman, N., Abramovich, B., Eitan, E., Elgrart, K., Beaulieu, D., Ennist, D. L., Berry, J. D., Paganoni, S., Shefner, J. M., & Drory, V. E. (2023). Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 24(3–4), 263–271. https://doi.org/10.1080/21678421.2022.2119868
Shamsaei, G., Houshmand, F., Ahmadzadeh Deylami, A., Valizadeh, A., Rafie, S., & Moradi, M. (2023). The Efficacy and Safety of Intrathecal Autologous Bone Marrow-Derived Mesenchymal Stromal Cells in Amyotrophic Lateral Sclerosis: A Pilot Study. Adv Pharm Bull, 13(2), 361–367. https://doi.org/10.34172/apb.2023.043
Sharygin, D., Koniaris, L. G., Wells, C., Zimmers, T. A., & Hamidi, T. (2023). Role of CD14 in human disease. Immunology, 169(3), 260–270. https://doi.org/https://doi.org/10.1111/imm.13634
Shefner, J. M., Andrews, J. A., Genge, A., Jackson, C., Lechtzin, N., Miller, T. M., Cockroft, B. M., Meng, L., Wei, J., Wolff, A. A., Malik, F. I., Bodkin, C., Brooks, B. R., Caress, J., Dionne, A., Fee, D., Goutman, S. A., Goyal, N. A., Hardiman, O., … Rudnicki, S. A. (2021). A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 22(3–4), 287–299. https://doi.org/10.1080/21678421.2020.1822410
Shefner, J., Oskarsson, B., Cohen, Y., Chen, K., Leitner, M., Berry, J., Macklin, E., Chibnik, L., Pothier, L., Geva, M., Goldberg, P., Hayden, M., Paganoni, S., & Cudkowicz, M. (2024). Pridopidine for the Treatment of ALS—Results from the Phase 2 Healey ALS Platform Trial (S5.003). Neurology, 102(17_supplement_1), 6524. https://doi.org/10.1212/WNL.0000000000206526
Silva-Moraes, M. H., Bispo-Torres, A. C., Barouh, J. L., Lucena, P. H., Armani-Franceschi, G., Dorea-Bandeira, I., Vieira, F., Miranda-Scippa, Â., Quarantini, L. C., Lucena, R., & Bandeira, I. D. (2020). Suicidal behavior in individuals with amyotrophic lateral sclerosis: A systematic review. Journal of Affective Disorders, 277, 688–696. https://doi.org/https://doi.org/10.1016/j.jad.2020.08.066
Siwek, T., Jezierska-Woźniak, K., Maksymowicz, S., Barczewska, M., Sowa, M., Badowska, W., & Maksymowicz, W. (2020). Repeat administration of bone marrow-derived mesenchymal stem cells for treatment of amyotrophic lateral sclerosis. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 26, e927484-1. https://doi.org/10.12659/MSM.927484
Thonhoff, J. R., Berry, J. D., Macklin, E. A., Beers, D. R., Mendoza, P. A., Zhao, W., Thome, A. D., Triolo, F., Moon, J. J., & Paganoni, S. (2022). Combined regulatory T-lymphocyte and IL-2 treatment is safe, tolerable, and biologically active for 1 year in persons with amyotrophic lateral sclerosis. Neurology: Neuroimmunology & Neuroinflammation, 9(6), e200019. https://doi.org/10.1212/NXI.0000000000200019
Tycińska, A., Gierlotka, M., Bugajski, J., Deja, M., Depukat, R., Gruchała, M., Grześk, G., Kasprzak, J. D., Kubica, J., Kucewicz Czech, E., Leszek, P., Płonka, J., Sobkowicz, B., Straburzyńska Migaj, E., Wilk, K., Zawiślak, B., Zymliński, R., & Stępińska, J. (2020). Levosimendan in the treatment of patients with acute cardiac conditions: an expert opinion of the Association of Intensive Cardiac Care of the Polish Cardiac Society. Kardiologia Polska, 78(7–8), 825–834. https://doi.org/10.33963/kp.15551
Tzeplaeff, L., Wilfling, S., Requardt, M. V., & Herdick, M. (2023). Current State and Future Directions in the Therapy of ALS. In Cells (Vol. 12, Issue 11). MDPI. https://doi.org/10.3390/cells12111523
Vallejo Camino, W. F., y Zambrano Robledo, S. J. (2019). Manejo de secreciones bronquiales en pacientes adultos con esclerosis lateral amiotrófica
Van Tress, J. J. (2020). Amyotrophic Lateral Sclerosis Patients’ Sociological Resilience, Self-Determination, and Decision-Making for Life-Sustaining Treatments [Doctoral dissertation, Walden University]. https://www.proquest.com/docview/2456893949?pq-origsite=gscholar&fromopenview=true
Wainger, B. J., Macklin, E. A., Vucic, S., McIlduff, C. E., Paganoni, S., Maragakis, N. J., Bedlack, R., Goyal, N. A., Rutkove, S. B., Lange, D. J., Rivner, M. H., Goutman, S. A., Ladha, S. S., Mauricio, E. A., Baloh, R. H., Simmons, Z., Pothier, L., Kassis, S. B., La, T., … Cudkowicz, M. E. (2021). Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Neurology, 78(2), 186–196. https://doi.org/10.1001/jamaneurol.2020.4300
Wang, G. Y., Rayner, S. L., Chung, R., Shi, B. Y., & Liang, X. J. (2020). Advances in nanotechnology-based strategies for the treatments of amyotrophic lateral sclerosis. Materials Today Bio, 6, 100055. https://doi.org/https://doi.org/10.1016/j.mtbio.2020.100055
Wood, H. (2021). Levosimendan fails to improve respiratory function in amyotrophic lateral sclerosis. Nature Reviews Neurology, 17(11), 660. https://doi.org/10.1038/s41582-021-00569-7
Xu, Q., Cho, J., Ben Chaouch, Z., & Lo, A. W. (2023). Incorporating patient preferences and burden-of-disease in evaluating ALS drug candidate AMX0035: a Bayesian decision analysis perspective. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 24(3–4), 281–288. https://doi.org/10.1080/21678421.2022.2136994
Xu, X., Shen, D., Gao, Y., Zhou, Q., Ni, Y., Meng, H., Shi, H., Le, W., Chen, S., & Chen, S. (2021). A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed? Translational Neurodegeneration, 10(1), 29. https://doi.org/10.1186/s40035-021-00250-5
Yamashita, T., Nakano, Y., Sasaki, R., Tadokoro, K., Omote, Y., Yunoki, T., Kawahara, Y., Matsumoto, N., Taira, Y., Matsuoka, C., Morihara, R., & Abe, K. (2023). Safety and Clinical Effects of a Muse Cell-Based Product in Patients With Amyotrophic Lateral Sclerosis: Results of a Phase 2 Clinical Trial. Cell Transplantation, 32, 09636897231214370. https://doi.org/10.1177/09636897231214370
Enlaces refback
- No hay ningún enlace refback.
Depósito Legal Electrónico: ME2016000090
ISSN Electrónico: 2610-797X
DOI: https://doi.org/10.53766/GICOS
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
Se encuentra actualmente registrada y aceptada en las siguientes base de datos, directorios e índices: | |||
![]() | ![]() | ![]() | |
![]() | ![]() | ![]() | ![]() |
![]() | ![]() | ![]() | ![]() |
![]() | ![]() | ![]() | ![]() |
![]() | ![]() | ![]() | ![]() |
![]() | ![]() | ![]() | ![]() |
![]() | ![]() |
Todos los documentos publicados en esta revista se distribuyen bajo una
Licencia Creative Commons Atribución -No Comercial- Compartir Igual 4.0 Internacional.
Por lo que el envío, procesamiento y publicación de artículos en la revista es totalmente gratuito.